| |
In this eBook discover more about the future of orphan drugs and the ways companies are enabling their drugs to get to market faster. Download today! 
|
|
|
Wednesday, January 25, 2023 | 1:00pm ET In this webinar, you’ll learn about a case study pursued in collaboration with Geneos Therapeutics and Personalis to utilize a tumor-informed ctDNA assay to retrospectively analyze clinical response to a class of personalized immunotherapies developed against tumor-specific neoantigens in advanced hepatocellular cancer (HCC) patients. Register now. 
|
|
| By Nick Paul Taylor Biogen has partnered with Alcyone Therapeutics to improve the delivery of its spinal muscular atrophy (SMA) drug Spinraza, handing over $10 million upfront for a global license to an implantable device. |
|
|
|
By Nick Paul Taylor Rani Therapeutics has secured a supply of ustekinumab for an oral drug delivery program, partnering with Celltrion to access materials for its development of a biosimilar rival to Johnson & Johnson’s Stelara. The deal gives Celltrion the right of first negotiation on the oral ustekinumab biosimilar program. |
By Nick Paul Taylor Cognos Therapeutics is coming to the Nasdaq. The implantable drug delivery specialist has agreed to merge with Nocturne Acquisition Corp. to secure a spot on the stock exchange and boost its bank balance. |
By Nick Paul Taylor Spiral Therapeutics has landed investor support for its sustained-release steroid candidate, raising $8.25 million to fund phase 2 development of a treatment for a debilitating inner ear disorder. |
|
Watch this OnDemand webinar to hear experts discuss a cross-functional approach to ensure appropriate containment systems for high potency products from development to commercialization. Download today! 
|
|
By Eric Sagonowsky,Zoey Becker,Angus Liu,Fraiser Kansteiner,Kevin Dunleavy On the second day of the J.P. Morgan Healthcare Conference, GSK, Bayer, Roche and many others are set to share updates about their operations. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now. 
|
|
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
eBook Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes. Sponsored by: Catalent |
| |
|
